[Renovascular safety of bevacizumab in breast cancer patients. The prognostic value of hypertension and proteinuria].
Fiche publication
Date publication
novembre 2015
Journal
Bulletin du cancer
Auteurs
Membres identifiés du Cancéropôle Est :
Dr JOUANNAUD Christelle
Tous les auteurs :
Launay-Vacher V, Janus N, Beuzeboc P, Daniel C, Ray-Coquard I, Selle F, Rey JB, Jouannaud C, Spano JP, Thery JC, Morere JF, Goldwasser F, Mir O, Oudard S, Scotté F, Dorent R, Ludwig L, Deray G, Gligorov J
Lien Pubmed
Résumé
The potential prognostic value of hypertension and proteinuria of anti-vascular endothelial growth factor (VEGF) drugs has not been assessed in routine clinical practice so far in breast cancer. The objectives of the MARS study were to assess the prevalence of proteinuria and hypertension at baseline, their incidence under anti-VEGF treatment, and to evaluate a possible link with overall survival.
Mots clés
Adult, Aged, Analysis of Variance, Angiogenesis Inhibitors, adverse effects, Bevacizumab, adverse effects, Breast Neoplasms, blood supply, Creatinine, blood, Female, France, epidemiology, Humans, Hypertension, epidemiology, Incidence, Kidney Function Tests, Middle Aged, Odds Ratio, Prevalence, Prognosis, Prospective Studies, Proteinuria, epidemiology, Survival Analysis, Vascular Endothelial Growth Factors, antagonists & inhibitors
Référence
Bull Cancer. 2015 Nov;102(11):906-14